)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Acrivon Therapeutics
Acrivon Therapeutics (ACRV) investor relations material
Acrivon Therapeutics Study Update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Study Update summary8 Jan, 2026
AP3 Platform and Pipeline Overview
The AP3 generative phosphoproteomics platform enables direct identification of drug effects on disease pathways, predictive biomarkers, and supports indication finding, resistance mechanism identification, and patient responder selection, fueling the clinical and preclinical pipeline.
Lead assets include phase II-B CHK1/2 inhibitor ACR-368, phase I dual WEE1/PKMYT1 inhibitor ACR-2316, and preclinical CDK11-targeting ACR-6840.
AP3-driven programs are expanding into auto-immune/inflammatory indications and additional oncology targets.
ACR-368 Phase II-B/2b Study in Endometrial Cancer
ACR-368 OncoSignature predicts benefit in biomarker-positive endometrial cancer, with a 39% overall response rate and over 80% disease control rate in arm one.
Serous subtype demonstrated a 67% confirmed response rate in biomarker-positive patients and 52% in all-comers with up to two prior therapies.
Arm three, enrolling up to 90 all-comer serous subjects in the US and EU, is ongoing with completion expected Q4 2026 and initial data update in mid-2026.
Subjects in Arm 3 will receive ACR-368 with ULDG sensitization, which may further increase response rates.
Phase III trial protocol for ACR-368 plus anti-PD-1 submitted to FDA, with global trial readiness anticipated mid-2026.
Market Opportunity and Clinical Context
Serous endometrial cancer accounts for 40% of endometrial cancer deaths, with a prevalence pool of 55,000-60,000 patients in the US and EU.
Current second- and third-line therapies offer limited benefit, with response rates of 10-15% and PFS of 2.5-3.5 months.
ACR-368's differentiated tolerability profile and high response rates position it competitively against ADCs, especially in later lines.
FDA feedback on ACR-368 Phase 3 protocol
ACR-2316 differentiation in SCLC/sqNSCLC
ACR-368 Arm 3 early readout potential
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Acrivon Therapeutics earnings date
Q4 202527 Mar, 2026
Acrivon Therapeutics
Next Acrivon Therapeutics earnings date
Q4 202527 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines. Utilizing its proprietary Acrivon Predictive Precision Proteomics (AP3) platform, the company advances drug candidates tailored to the predicted sensitivity of tumors to specific medicines. The company is headquartered in Watertown, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage